In 2010, two former Merck virologists filed a False Claims Act complaint alleging that the pharmaceutical giant had deliberately falsified efficacy data for its mumps vaccine. The complaint, filed by Stephen Krahling and Joan Wlochowski, remained sealed for two years before becoming public — and the allegations it contained were staggering in scope.
What the Whistleblowers Alleged
According to the complaint, Merck knowingly manipulated test results to fabricate a 95 percent efficacy rate for its mumps vaccine. The company allegedly spiked blood samples with animal antibodies to artificially inflate the appearance of immune system response. Court documents stated that these animal antibodies created a laboratory scenario that bore no resemblance to actual virus neutralization in vaccinated individuals.
The whistleblowers further alleged that Merck used these fabricated trial results to secure hundreds of millions of dollars in government contracts for a vaccine that did not provide adequate immunization. According to their account, this scheme had been operating since the late 1990s, and the vaccine was never tested against real-world mumps viruses circulating in the population.
Perhaps most troubling, the complaint stated that this entire operation was carried out “with the knowledge, authority and approval of Merck’s senior management.” Both scientists claimed they witnessed firsthand the improper testing and data falsification used to inflate the vaccine’s reported effectiveness.
The Government’s Response — or Lack Thereof
When the False Claims Act was filed in 2010, the U.S. government effectively chose not to act on it. Rather than investigating the allegations and holding Merck accountable, federal authorities allowed the complaint to remain sealed and took no visible enforcement action. Critics argued this amounted to protecting a market monopoly rather than serving justice, raising serious questions about the relationship between regulators and the vaccine industry.
A Medical Practice Takes Legal Action
The unsealing of the whistleblower complaint prompted Chatom Primary Care, an Alabama-based medical practice, to file its own lawsuit against Merck. The suit alleged that the company had engaged in a decade-long scheme to falsify and misrepresent the true efficacy of its mumps vaccine.
Among the lawsuit’s key allegations:
Merck fraudulently represented that its mumps vaccine maintained a 95 percent or higher efficacy rate, while knowing through its own internal testing that this figure was false. The company allegedly designed a testing methodology using a less virulent mumps strain, then abandoned and concealed the results when they failed to meet desired benchmarks. Court filings also described the destruction of evidence, lies told to an FDA investigator, and threats of imprisonment directed at a Merck vaccine division virologist who considered reporting the fraud.
The Chatom lawsuit pointed to the real-world consequences of this alleged deception: millions of children receiving a vaccine that did not adequately protect them against mumps. The suit specifically cited mumps outbreaks in the Midwest in 2006 and elsewhere in 2009 as evidence that the vaccine’s failure was allowing the disease to persist rather than being eradicated as the CDC had projected.
Monopoly Power Through Fraudulent Claims
The legal filings also alleged that Merck leveraged its fabricated efficacy data to monopolize the mumps vaccine market. By claiming a 95 percent effectiveness rate that competitors could not match — because the number was allegedly fictional — Merck was able to eliminate competition and maintain exclusive government contracts. The Chatom lawsuit included claims under the Sherman Act for monopolization, along with breach of warranty and consumer protection violations.
Why This Case Matters
The Merck whistleblower case raised fundamental questions about oversight in the pharmaceutical industry. If two company scientists felt compelled to file a federal complaint alleging systematic fraud, and the government’s initial response was to do nothing, it suggests deep structural problems in how vaccine safety and efficacy are verified and enforced.
Merck denied all allegations in the case. The legal proceedings that followed would take years to work through the courts, but the core questions raised by Krahling and Wlochowski’s complaint — about data integrity, regulatory independence, and public accountability in vaccine development — remain relevant to ongoing debates about pharmaceutical transparency and consumer protection.
